Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Post-marketing oncology studies: Enabling faster recruitment and lower costs
  • Commercial

Post-marketing oncology studies: Enabling faster recruitment and lower costs

Pharmaceutical Technology

In clinical trials, post-marketing approval studies remain a lower priority than other research areas, especially at community oncology centers.

Oncology

Read full story

pharminent June 22, 2026 (Last updated: June 22, 2026)

Pharmaceutical Technology

In clinical trials, post-marketing approval studies remain a lower priority than other research areas, especially at community oncology centers.

Oncology

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sun Pharma to acquire Innovcare Lifesciences for $28.7m
Next: Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

Related Stories

  • Commercial

The first 14 days: How specialty programs set patients up for success

pharminent June 22, 2026
  • Commercial

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

pharminent June 19, 2026
  • Commercial

Moderna builds commercial muscle as new launches loom

pharminent June 17, 2026

You May Have Missed

  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
  • Clinical Data

Boehringer advances duo for aggressive cancers into phase 3

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.